Literature DB >> 17627171

Prostate biopsy in Central Europe: results of a survey of indication, patient preparation and biopsy technique.

Klaus G Fink1, Hans-Peter Schmid, Ljiljana Paras, Nikolaus T Schmeller.   

Abstract

OBJECTIVE: We surveyed urologists in Austria, Germany and Switzerland regarding their standard approach to prostate biopsy.
METHODS: Participants of Austrian and German urological meetings were asked to fill out a survey form; additionally, this was mailed to all Swiss urologists.
RESULTS: 304 surveys are available for analysis. 97% of participants perform a biopsy if digital rectal examination is abnormal. 63% use 4 ng/ml PSA (prostate-specific antigen) as cut-off. Age-related reference ranges are used by 54%, free PSA by 57%. 22% use PSA density, 55% PSA velocity. Overall 61% require a written consent, with 85, 86 and 25% in Austria, Germany and Switzerland. 96% of the urologists prescribe a quinolone antibiotic with a wide range regarding the start and end of drug therapy. 77% offer some kind of anaesthesia. Periprostatic injection of a local anaesthetic drug is used by 36%, lidocaine gel by 27%. 91% perform the biopsies transrectally under ultrasound guidance. Digitally guided biopsies are used by 11%. Only 3 participants perform perineal biopsies. The mean number of cores per biopsy session is 9.2, the maximum number of cores is 15.3 as a mean. Participants will stop performing any further biopsies if the patient already had a mean of 3.5 biopsy sessions.
CONCLUSIONS: The majority of urologists in Central Europe prescribe a quinolone antibiotic and recommend some type of analgesia. The majority has abandoned the sextant technique and increases the number of cores in the case of rebiopsy. Biopsies are stopped after a mean of 3.5 sessions.

Entities:  

Mesh:

Year:  2007        PMID: 17627171     DOI: 10.1159/000102916

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  2 in total

1.  Does periprostatic block reduce pain during transrectal prostate biopsy? A randomized, placebo-controlled, double-blinded study.

Authors:  Michael S Ingber; Ibrahim Ibrahim; Cynthia Turzewski; Jay B Hollander; Ananias C Diokno
Journal:  Int Urol Nephrol       Date:  2009-08-08       Impact factor: 2.370

2.  Do additional cores from cancer-suspicious lesions on transrectal ultrasound improve prostate cancer detection including index tumors over 12-core systematic biopsy?

Authors:  Jung Ki Jo; Sung Kyu Hong; Seok-Soo Byun; Sang Eun Lee; Seong Jin Jeong
Journal:  Cancer Manag Res       Date:  2018-05-10       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.